Scleroderma

Researchers in Italy developed a clear way of exploring differences in autoantibodies to predict which scleroderma patients are likely to develop pulmonary arterial hypertension (PAH), improving their chances of getting appropriate treatment ... Read more

February 15, 2016February 15, 2016

PAH Patients with Anti-U1 RNP Antibodies Better Protected Against Worst Aspects of Disease

News, PAH News, Scleroderma

People with connective tissue disease (CTD) and systemic sclerosis-associated pulmonary arterial hypertension (PAH) who are positive for anti-U1 RNP antibodies have better chances of longer-term survival. The study, “Characteristics and Survival of ... Read more

December 21, 2015

Systemic Sclerosis and Lung Fibrosis Study of Nintedanib Enrolls First Patient

Pulmonary Fibrosis News, Scleroderma

Boehringer Ingelheim recently announced the enrollment of the first patient in its global, double-blind, randomized, and placebo-controlled SENSCIS (Safety and Efficacy of Nintedanib in Systemic SClerosIS) Phase 3 clinical trial. The trial (NCT02597933) is now ... Read more

September 16, 2015September 16, 2015

Study Demonstrates Benefit of Cytori’s Scleroderma Treatment After One Year

News, Scleroderma

Cytori Therapeutics recently published a report of 12-month data from the Scleradec-I clinical trial studying hand dysfunction in people with scleroderma. Findings from the 12 patient trial, which was led by Dr. ... Read more

August 20, 2015August 20, 2015

Resunab by Corbus Pharmaceuticals Granted Fast Track Development Status by FDA for Systemic Sclerosis

News, Scleroderma

Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company focused on addressing rare, chronic, and serious inflammatory and fibrotic diseases, recently announced that the US Food and Drug Administration has ... Read more

August 6, 2015November 6, 2015

Autoantibodies Not Associated With Death in SSc-PAH Patients

News, Scleroderma

A variety of biomarkers are elevated in the serum of patients with systemic sclerosis-pulmonary arterial hypertension (SSc-PAH). Researchers have mostly been studying these markers to determine if they can ... Read more

July 6, 2015July 6, 2015

Roche’s ESBRIET (pirfenidone) Deemed Safe in Systemic Sclerosis Patients with Interstitial Lung Disease

News, Scleroderma

Results showing the safety of Esbriet (pirfenidone) in treating interstitial lung disease due to systemic sclerosis were recently presented at the European League Against Rheumatism Annual European Congress of ... Read more

May 25, 2015October 26, 2015

Highest Risk Of Pulmonary Arterial Hypertension Observed In Patients With Systemic Scleroderma

News, PAH News, Scleroderma

Scleroderma has often been associated with a higher risk of pulmonary arterial hypertension (PAH) in previous research. This is because in patients with scleroderma, there is progressive blood vessel contraction ... Read more

May 21, 2015May 21, 2015

HRCT Predicts Lung Function Decline in SSc Patients

News, Pulmonary Fibrosis News, Scleroderma

Patients with systemic sclerosis (SSc) are at an increased risk for mortality due to concurrent pulmonary hypertension or interstitial lung disease. While pulmonary hypertension results in right-sided heart failure, ... Read more

March 11, 2015March 11, 2015

FDA Clears Corbus’ IND to Start Phase 2 Scleroderma Treatment Study

News, Scleroderma

Clinical stage pharmaceutical company Corbus Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND) application allowing the company to begin a phase 2 clinical study to evaluate ... Read more